Literature DB >> 3801769

The protective action of allopurinol in an experimental model of haemorrhagic shock and reperfusion.

G Allan, D Cambridge, L Lee-Tsang-Tan, C W Van Way, M V Whiting.   

Abstract

Haemorrhagic shock was induced in anaesthetized, open-chest dogs by controlled arterial bleeding, sufficient to reduce and maintain mean arterial blood pressure at 40 mmHg for 30 min. The blood volume was then restored to the pre-shock level by rapid, intravenous reinfusion of the blood shed during the shock period. Haemorrhagic shock produced significant haemodynamic changes, characterized by a marked depression of myocardial function. Cardiac output (1226 +/- 57 ml min-1), peak aortic blood flow (6030 +/- 383 ml min-1) and maximum rate of rise of left ventricular pressure (2708 +/- 264 mmHg s-1) were all reduced by more than 50%. The haemodynamic profile was markedly improved by reinfusion of shed blood but this improvement was not sustained. There was a gradual decline such that 50% of the untreated animals suffered complete circulatory collapse and death between 60 and 120 min following reinfusion. Neither haemorrhagic shock, nor reinfusion of shed blood produced any consistent or significant changes in the myocardial adenine nucleotide pool. The ATP, ADP and AMP levels were, respectively, 25.9 +/- 4.2; 15.6 +/- 1.0; 4.3 +/- 1.9 nmol g-1 protein, before haemorrhagic shock; 21.6 +/- 3.4; 21.5 +/- 2.5; 10.2 +/- 2.7 nmol g-1 protein, after 30 min haemorrhagic shock; and 29.9 +/- 3.9; 16.5 +/- 1.2; 4.2 +/- 1.1 nmol g-1 protein, 60 min following reinfusion of shed blood. Pretreatment with allopurinol (50.0 mg kg-1 i.v.), 60 min before inducing haemorrhagic shock, had no significant effect upon the haemodynamic response to shock, but did prevent the gradual decline seen following reinfusion in the untreated animals. All of the allopurinol-treated animals displayed significantly better haemodynamic profiles than the untreated animals, furthermore, there was a 100% survival rate in this group. 5 Allopurinol had no significant effect upon the myocardial adenine nucleotide pool either during haemorrhagic shock or following reinfusion of shed blood.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3801769      PMCID: PMC1917055          DOI: 10.1111/j.1476-5381.1986.tb11130.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Insufficient coronary flow and myocardial failure as a complication factor in late hemorrhagic shock.

Authors:  S J SARNOFF; R B CASE; P E WAITHE; J P ISAACS
Journal:  Am J Physiol       Date:  1954-03

2.  Protection against irreversible hemorrhagic shock by allopurinol.

Authors:  C H Baker
Journal:  Proc Soc Exp Biol Med       Date:  1972-11

3.  Cardiac and skeletal muscle metabolic energy stores in hemorrhagic shock.

Authors:  A M Lefer; J C Daw; R M Berne
Journal:  Am J Physiol       Date:  1969-03

4.  Superoxide dismutase plus catalase enhances the efficacy of hypothermic cardioplegia to protect the globally ischemic, reperfused heart.

Authors:  M Shlafer; P F Kane; M M Kirsh
Journal:  J Thorac Cardiovasc Surg       Date:  1982-06       Impact factor: 5.209

Review 5.  Oxygen-derived free radicals in postischemic tissue injury.

Authors:  J M McCord
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

6.  Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase.

Authors:  S R Jolly; W J Kane; M B Bailie; G D Abrams; B R Lucchesi
Journal:  Circ Res       Date:  1984-03       Impact factor: 17.367

7.  Failure of the xanthine oxidase inhibitor allopurinol to limit infarct size after ischemia and reperfusion in dogs.

Authors:  K A Reimer; R B Jennings
Journal:  Circulation       Date:  1985-05       Impact factor: 29.690

8.  Effect of a xanthine oxidase inhibitor on adenine nucleotide degradation in hemorrhagic shock.

Authors:  S K Cunningham; T V Keaveny
Journal:  Eur Surg Res       Date:  1978       Impact factor: 1.745

Review 9.  The stunned myocardium: prolonged, postischemic ventricular dysfunction.

Authors:  E Braunwald; R A Kloner
Journal:  Circulation       Date:  1982-12       Impact factor: 29.690

10.  Cardiac performance in hemorrhagic shock.

Authors:  S E Downing
Journal:  Tex Rep Biol Med       Date:  1979
View more
  7 in total

Review 1.  The proteasome: a central regulator of inflammation and macrophage function.

Authors:  Nilofer Qureshi; Stefanie N Vogel; Charles Van Way; Christopher J Papasian; Asaf A Qureshi; David C Morrison
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Molecular basis of protective effect by crocetin on survival and liver tissue damage following hemorrhagic shock.

Authors:  Animesh Dhar; George Cherian; Gopal Dhar; Gibanananda Ray; Ram Sharma; Sushanta K Banerjee
Journal:  Mol Cell Biochem       Date:  2005-10       Impact factor: 3.396

3.  Cell shock.

Authors:  T V Keaveny
Journal:  Ir J Med Sci       Date:  1988-05       Impact factor: 1.568

4.  Effects of inhibitors of the activity of poly (ADP-ribose) synthetase on the organ injury and dysfunction caused by haemorrhagic shock.

Authors:  M C McDonald; H M Filipe; C Thiemermann
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

Review 5.  Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.

Authors:  Pál Pacher; Alex Nivorozhkin; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

Review 6.  Drug antioxidant effects. A basis for drug selection?

Authors:  B Halliwell
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

7.  Allopurinol attenuates acute kidney injury following Bothrops jararaca envenomation.

Authors:  Pedro Henrique França Gois; Monique Silva Martines; Daniela Ferreira; Rildo Volpini; Daniele Canale; Ceila Malaque; Renato Crajoinas; Adriana Castello Costa Girardi; Maria Heloisa Massola Shimizu; Antonio Carlos Seguro
Journal:  PLoS Negl Trop Dis       Date:  2017-11-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.